[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.175.236. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
April 1988

Recombinant Interferon Gamma in Psoriasis

Author Affiliations

Department of Dermatology University of Köln D-5000 Köln 41, West Germany

Arch Dermatol. 1988;124(4):487-488. doi:10.1001/archderm.1988.01670040007003
Abstract

To the Editor.—  We read with great interest the recent article by Morhenn et al1 entitled "Use of Recombinant Interferon Gamma Administered Intramuscularly for the Treatment of Psoriasis." Their results are in good agreement with those we reported previously,2,3 showing that systemic treatment of psoriasis with recombinant interferon-gamma (rIFN-gamma) (1) leads to the expression of HLA-DR antigen on keratinocytes in psoriatic lesions in vivo, (2) nevertheless does not clear psoriatic lesions, and (3) may increase the serum triglycéride level. In fact, these findings were presented at the Dermatopharmacology Symposium, at Stanford (Calif) in 1985, the Fourth International Symposiumon Psoriasis, at Stanford (Calif) in 1986, and at the on Psoriasis, at Stanford (Calif) in 1986, and at the 45th annual meeting of the American Academy of Dermatology, at New Orleans in 1986.Morhenn et al1 injected rIFN-gamma intramuscularly and suggested that "intralesional administration of rIFN-gamma might prove advantageous."

First Page Preview View Large
First page PDF preview
First page PDF preview
×